Eisai Clinical Trials

An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors

E7080-J081-103

Study Overview

E7080
lenvatinib
NCT00280397
Jan 2006 - Sep 2008
Solid Tumors
Maximum tolerated dose (MTD) estimated from Dose limiting toxicity (DLT)

  • Age 18+ males and females

  • Completed

  • Phase 1

  • Japan

Results

CSR Synopsis

Download PDF

Lay Summary

No download available

Publication reference citation

Koyama N, Saito K, Nishioka Y, Yusa W, Yamamoto N, Yamada Y, et al. Pharmacodynamic change in plasma angiogenic proteins: A dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib. BMC Cancer 2014 Jul 21;14(1). DOI: 10.1186/1471-2407-14-530

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

Redacted documents are available upon request for this study.

Document type Availability
Protocol
SAP
Sample CRF
Full CSR